Oxford spin-outs have been busy raising finance. A total of nearly £50 million has been secured so far this year by some of the 50 companies spun-out by Oxford University Innovation from the University of Oxford, including those mentioned below.
We publish news of technology innovations, investment opportunities, together with updates from spinout & startup companies and licensees
Oxford University has signed a private equity deal, initially worth £12m, to help the funding of its new Institute of Biomedical Engineering (IBME) www.ibme.ox.ac.uk. The deal, struck with London’s City-based Technikos, also includes the provision of commercial and financial advice and assistance in return for shares in future spin-outs from IBME.
VASTox, a leading chemical genomics company, has announced that it has successfully raised £10.45 million in a placing of New Ordinary Shares to institutional investors.
BioAnaLab Limited, a specialist contract analytical laboratory, has recently achieved full membership of the United Kingdom Good Laboratory Practice (GLP) Compliance Programme.
The latest spin-out company from Oxford University, Oxford Catalysts Ltd, plans to develop and exploit novel catalyst technology for the energy industry which is both cost-effective and environmentally friendly.
Third Phase Limited, a high-tech company spun out from Oxford University's Department of Engineering Science and now based on the Cambridge Science Park, is pleased to announce that it has merged with the Cmed Group Ltd, opening up tremendous development opportunities for both companies.
A new spin-out from Oxford University, Spinox, is aiming to devise novel ways to copy spiders' ability to spin silks. The new silks may be used for sutures or woven material for surgical implants, protective clothing and in sports equipment.
BioAnalab Limited, the Oxford-based specialist contract analytical laboratory, today announced the successful completion of a further round of private equity funding totalling £440,000. The round was led by Octopus Asset Management, who invested £250,000 through the BioScience Venture Capital Trust.